The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been ‘forked’ from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.
A major challenge in synthetic biology, particularly for mammalian systems, is the inclusion of adequate external control for the synthetic system activities. Control at the transcriptional level can be achieved by adaptation of bacterial repressor–operator systems (e.g., TetR), but altering the activity of a protein by controlling transcription is indirect and for longer half-life mRNAs, decreasing activity this way can be inconveniently slow. Where possible, direct modulation of protein activity by soluble ligands has many advantages, including rapid action. Decades of drug discovery and pharmacological research have uncovered detailed information on the interactions between large numbers of small molecules and their primary protein targets (as well as off-target secondary interactions), many of which have been well studied in mammals, including humans. In principle, this accumulated knowledge would be a powerful resource for synthetic biology. Here, we present SynPharm, a tool that draws together information from the pharmacological database GtoPdb and the structural database, PDB, to help synthetic biologists identify ligand-binding domains of natural proteins. Consequently, as sequence cassettes, these may be suitable for building into engineered proteins to confer small-molecule modulation on them. The tool has ancillary utilities which include assessing contact changes among different ligands in the same protein, predicting possible effects of genetic variants on binding residues, and insights into ligand cross-reactivity among species.
Ever-increasing volumes of sequencing data offer potential for large-scale meta-analyses to address significant biological questions. However, challenges such as insufficient data processing information, data quality concerns, and issues related to accessibility and curation often present obstacles. Additionally, most experimental biologists lack the time and expertise needed to independently analyse, manage and share their own data. To overcome these hurdles, we present Flow, a web-based platform that links bioinformatic analysis and database solutions with a user-friendly interface and web API. Flow currently accommodates a range of genomics methods and further DSL2-compliant Nextflow pipelines can be added via a simple JSON schema file. Deployable on local systems or cloud services, an instance is freely accessible to academic researchers at https://flow.bio .
IgA nephropathy (IgAN) is characterized by mesangial deposition of J-chain containing dimeric IgA1 (dIgA1). Given that deposited IgA1 is mostly dIgA1, solution structure determinations of dIgA1 in phenotyped patients may be relevant to the pathogenesis of IgAN. Thus, dIgA1 from three IgAN patients and a healthy control were isolated. Biochemically, the dIgA1 structures were correlated with serum IgA-IgG immune complex levels, activated human mesangial cells IL-6 production, and the pattern of IgA1 N- and O-glycosylation. The degree of dIgA1 hinge O-glycosylation varied between the four subjects, being lower in IgAN subjects with an active renal biopsy Oxford score and clinically progressive IgAN. Their solution structures were investigated using analytical ultracentrifugation and small angle X-ray and neutron scattering. The increased O-glycosylation of the dIgA1 hinge was associated with larger X-ray radii of gyration Rg0 (healthy control, 8.75±0.05 nm; patient A, 8.90±0.06 nm) compared to subjects with reduced O-glycosylation that showed more compact structures (patient B, 8.62±0.05 nm and patient C, 8.62±0.07 nm). Similar findings were observed by neutron scattering. Atomistic modelling of the X-ray data identified 100 best-fit structures that accounted for the scattering curves for each of the four dIgA1 samples. Analysis of these structures showed that the angle between the main axes of the two monomers in the dimeric structures for the three patients is slightly reduced compared to that of the healthy control. This difference implicates conformational change in the overall dIgA1 structure that may increase mesangial IgA deposition and ability to generate renal injury.